Abbott Laboratories $ABT Shares Sold by Moran Wealth Management LLC

Moran Wealth Management LLC reduced its stake in shares of Abbott Laboratories (NYSE:ABT) by 97.7% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 1,709 shares of the healthcare product maker’s stock after selling 73,546 shares during the quarter. Moran Wealth Management LLC’s holdings in Abbott Laboratories were worth $214,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in ABT. Harbor Capital Advisors Inc. acquired a new stake in shares of Abbott Laboratories during the fourth quarter worth $27,000. Cloud Capital Management LLC acquired a new stake in shares of Abbott Laboratories during the third quarter worth $29,000. Guerra Advisors Inc acquired a new stake in shares of Abbott Laboratories during the third quarter worth $31,000. Bridge Generations Wealth Management LLC acquired a new stake in shares of Abbott Laboratories during the third quarter worth $33,000. Finally, Copia Wealth Management acquired a new stake in shares of Abbott Laboratories during the third quarter worth $38,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ABT has been the subject of several research reports. Stifel Nicolaus lowered their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. JPMorgan Chase & Co. decreased their target price on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Evercore decreased their target price on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating for the company in a research report on Friday, April 17th. UBS Group decreased their target price on shares of Abbott Laboratories from $158.00 to $135.00 and set a “buy” rating for the company in a research report on Monday. Finally, Barclays decreased their target price on shares of Abbott Laboratories from $144.00 to $143.00 and set an “overweight” rating for the company in a research report on Monday. Two research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $120.35.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: UBS kept a “buy” rating on ABT, signaling continued conviction in Abbott’s franchise despite trimming its price target — a vote of confidence from a major bank. UBS Sticks to Their Buy Rating for Abbott Laboratories (ABT)
• Positive Sentiment: Income-minded investors are seeing value: recent coverage highlights a dividend yield near 3% and labels ABT a “dividend king” opportunity for buy-the-dip investors. That supports demand from yield-focused funds. Abbott Laboratories Just Got Interesting: Dividend Yield Near 3% Signals Opportunity
• Positive Sentiment: Progress on Abbott’s CancerGuard multi-cancer early-detection program and new DETECT A outcomes reinforce the company’s long-term diagnostics growth narrative. Positive clinical/award news can support upside over time. Abbott’s CancerGuard Progress Adds New Dimension To Diagnostics Growth Story
• Neutral Sentiment: Options-market activity is drawing attention; spikes in put/call flows can foreshadow moves but aren’t a directional confirmation by themselves. Traders may use this as a signal for volatility, not fundamentals. Is the Options Market Predicting a Spike in Abbott Laboratories Stock?
• Neutral Sentiment: Coverage notes that ABT is trading near its 52-week low while many analysts remain bullish — an outlook that supports buy-side interest if sentiment stabilizes. Wall Street Refuses to Blink: 2 Healthcare Stocks at 52-Week Lows That Analysts Still Love
• Negative Sentiment: Major banks collectively trimmed price targets (multiple firm actions published), creating downward pressure on the stock as headline PT cuts refresh sell-side valuation estimates. This broad re-rating is a primary driver of today’s weakness. Mizuho Cuts Abbott Laboratories Price Target
• Negative Sentiment: UBS and Argus lowered their targets (UBS to $135; Argus to $125) even while keeping buy ratings — a mixed signal that reduces near-term upside expectations vs. prior levels. UBS Adjusts Abbott Laboratories Price Target to $135
• Negative Sentiment: Social and analyst chatter highlights that Q1 results beat estimates but management trimmed full-year guidance (diagnostics headwinds, mild flu season, acquisition costs), which triggered post-earnings selling and still weighs on sentiment. Abbott Laboratories Stock Opinions on Q1 Earnings and Guidance Cut

Abbott Laboratories Stock Down 3.3%

ABT opened at $92.83 on Wednesday. Abbott Laboratories has a fifty-two week low of $92.65 and a fifty-two week high of $139.06. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.18 and a current ratio of 1.58. The company has a fifty day moving average of $107.21 and a two-hundred day moving average of $118.00. The stock has a market capitalization of $161.67 billion, a price-to-earnings ratio of 26.00, a PEG ratio of 1.60 and a beta of 0.79.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.71%. The company had revenue of $11.16 billion during the quarter, compared to analysts’ expectations of $10.99 billion. During the same quarter in the previous year, the company earned $1.09 earnings per share. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. On average, research analysts expect that Abbott Laboratories will post 5.53 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.7%. Abbott Laboratories’s payout ratio is presently 70.59%.

Insider Buying and Selling

In other news, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction on Wednesday, February 4th. The stock was bought at an average price of $108.73 per share, with a total value of $1,087,300.00. Following the completion of the acquisition, the director owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. This represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the sale, the executive vice president directly owned 146,377 shares of the company’s stock, valued at $16,918,253.66. This represents a 0.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 3,055 shares of company stock valued at $353,097 in the last ninety days. Company insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.